Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 13922 Download: 381 Citations: 38

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 7169 Download: 152 Citations: 15

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Soon Young Ko, Won Hyeok Choe

Clin Mol Hepatol. 2018;24(4):351-357. Published online March 16, 2018

DOI: https://doi.org/10.3350/cmh.2017.0063

View: 9225 Download: 344 Citation: 1

Management of direct antiviral agent failures

María Buti, Rafael Esteban

Clin Mol Hepatol. 2016;22(4):432-438. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0107

View: 10650 Download: 362 Citations: 26

Original Article

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song

Clin Mol Hepatol. 2016;22(2):259-266. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0020

View: 9034 Download: 161 Citations: 7

Artificial intelligence predicts direct-acting antivirals failure among HCV patients: A Nationwide HCV Registry Program

Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng, Chun-Wei- Tsai, Chi-Yi Chen, Ming-Lung Yu

Received August 2, 2023 Accepted November 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0287 [Accepted]

View: 78 Download: 4

1 |

Viewed By 5385	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4809	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 4164	MAFLD: How is it different from NAFLD?
Viewed By 3956	A decade of liver organoids: Advances in disease modeling
Viewed By 2972	Management of refractory ascites

Cited By 128	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 76	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 57	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 55	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 51	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Search